Home/Pipeline/AVAT-031

AVAT-031

Schizophrenia

DiscoveryActive

Key Facts

Indication

Schizophrenia

Phase

Discovery

Status

Active

Company

Avata Biosciences

About Avata Biosciences

Avata Biosciences is a UK-based clinical-stage biotech leveraging a proprietary formulation technology to transform synthetic cannabinoids into water-soluble, solid-dose oral medicines. Its lead programs target significant unmet needs in adult and pediatric focal epilepsy and schizophrenia, with a strategy to utilize the FDA's 505(b)(2) regulatory pathway. The company is led by a seasoned team with deep experience from GW Pharmaceuticals and has established a key co-development partnership for the Asian market.

View full company profile

Therapeutic Areas

Epilepsy Schizophrenia Addiction Neurology Psychiatry

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active